Study of Carboplatin and Paclitaxel for Ovarian Cancer
Author Information
Author(s): N Siddiqui, AV Boddy, HD Thomas, NP Bailey, L Robson, MJ Lind, AH Calvert
Primary Institution: Northern Centre for Cancer Treatment, Newcastle General Hospital; Department of Oncology, University of Newcastle upon Tyne
Hypothesis
The study aims to determine the maximum tolerated dose of a combination of carboplatin and paclitaxel and evaluate any possible pharmacokinetic interaction.
Conclusion
The combination of carboplatin and paclitaxel may be administered as first-line treatment for advanced ovarian cancer, with manageable toxicity.
Supporting Evidence
- Grade 3 or 4 neutropenia was seen in 70% of the courses.
- Grade 3 or 4 thrombocytopenia occurred in 24% of the courses.
- The AUC of carboplatin was 7.0±1.4 mg ml-' min, indicating no pharmacokinetic interaction.
- Ten patients completed the treatment of six cycles each.
Takeaway
Doctors wanted to find out how much of two cancer drugs, carboplatin and paclitaxel, can be given together safely to help women with ovarian cancer.
Methodology
This phase I study involved treating twelve chemonaive patients with escalating doses of paclitaxel followed by carboplatin, with pharmacokinetic studies performed on nine patients.
Limitations
The results need to be confirmed in future investigations due to the small sample size.
Participant Demographics
Patients were aged between 18-75 years, with histologically proven epithelial ovarian cancer.
Want to read the original?
Access the complete publication on the publisher's website